A comparative cross-sectional study investigating prevalence and patterns of sexual dysfunction among hypertensive and non-hypertensive men

Year 2022, Volume: 52 Issue: 3, 324 - 331, 30.12.2022

Akinwumi Akinyede , Adedunni Olusanya , Hazees Mohammed , Olumuyiwa Fasipe , Adesina Arikawe

https://doi.org/10.26650/IstanbulJPharm.2022.975375

Abstract

Background and Aims: Erectile dysfunction is prevalent among men with hypertension, but there is paucity of data on preva- lence of other domains of sexual dysfunction (SD) in hypertensives and the general population. The study compared the prevalence and patterns of SD among treated hypertensive male patients with normotensive men. The effect of antihyper- tensive drugs on different domains of sexual function was also investigated in our study.
Methods: A total of 195 participants (95 hypertensive and 100 non-hypertensive men) were recruited from the medical out- patient department of a secondary health care facility in Lagos, Nigeria. Sexual function was assessed using International Index of Erectile Function (IIEF) which measures erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction.
Results: Sexual dysfunction affecting at least one domain was present in 82.1% of the hypertensive subjects and 52% of non- hypertensive controls (P<0.001). The hypertensive patient had more severe dysfunction in the multiple domains (p< 0.001). The use of methyldopa, furosemide and ß-blockers were associated with significantly lower scores while there was no signifi- cant difference in scores with the use calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, thiazide and potassium sparing diuretics. SD was higher in the older age group and with longer duration of hyperten- sion and treatment.
Conclusion: SD is common in the adult male population with hypertension significantly increasing the risk. Hypertension is associated with involvement of multiple domains for sexual dysfunction. Use of methyldopa, furosemide and ß-blockers were associated with higher rates of SD in the hypertensive population.

Keywords

Hypertension, Sexual dysfunction, Erectile dysfunction, Antihypertensive drugs

References

• Akinyede, A. A., Nwaiwu, O., Fasipe, O. J., Olusanya, A., Olayemi, S. O., & Akande, B. (2020). A prospective study of the effect of antihy- pertensive medications on the sexual functions of hypertensive adult male patients. Future Science OA, 6(6), FSO479. doi:10.2144/ fsoa-2020-0030
• Artom, N., Pinna, G., Musso, N. R., Orlandini, F., Malasoma, P., Uc- celli, M., . . . Pende, A. (2016). Prevalence of erectile dysfunction in a cohort of Italian hypertensive subjects. Clinical and Experimental Hypertension, 38(2), 143-149. doi:10.3109/10641963.2015.1060994
• Bleustein, C. B., Arezzo, J. C., Eckholdt, H., & Melman, A. (2002). The neuropathy of erectile dysfunction. International Journal of Impo- tence Research, 14(6), 433-439. doi:10.1038/sj.ijir.3900907.
• Burnett, A. L. (2019). The science and practice of erection physiol- ogy: story of a revolutionary gaseous molecule. Transactions of the American Clinical and Climatological Association, 130, 51-59.
• Chen, L., Shi, G. R., Huang, D. D., Li, Y., Ma, C. C., Shi, M., . . . Shi, G. J. (2019). Male sexual dysfunction: A review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention. Biomedicine and Pharmacotherapy, 112, 108585. doi:10.1016/j.biopha. 2019.01.046
• Doumas, M., Tsakiris, A., Douma, S., Grigorakis, A., Papadopoulos, A., Hounta, A., . . . Giamarellou, H. (2006). Factors affecting the increased prevalence of erectile dysfunction in Greek hyperten- sive compared with normotensive subjects. Journal of Andrology, 27(3), 469-477. doi:10.2164/jandrol.04191
• Derogatis, L. R., & Burnett, A. L. (2008). The epidemiology of sex- ual dysfunctions. The Journal of Sexual Medicine, 5(2), 289-300. doi:10.1111/j.1743-6109.2007.00668.x
• Ekman, E., Hägg, S., Sundström, A., & Werkström, V. (2010). Antihy- pertensive drugs and erectile dysfunction as seen in spontane- ous reports, with focus on angiotensin II type 1 receptor block- ers. The Drug, Healthcare and Patient Safety, 2, 21-25. doi:10.2147/ dhps.s8432.
• Fafiolu, A. S., Adebayo, A. M., Akande, T. O., & Akinboboye, O. O. (2014). Erectile dysfunction among male hypertensives in a ter- tiary health facility in South-West Nigeria. Global Journal of Health Science, 7(1), 154-160. doi:10.5539/gjhs.v7n1p154
• Fogari, R., & Zoppi, A. (2002). Effects of antihypertensive therapy on sexual activity in hypertensive men. Current Hypertension Re- ports, 4(3), 202-210. doi:10.1007/s11906-002-0008-3
• Foy, C. G., Newman, J. C., Berlowitz, D. R., Russell, L. P., Kimmel, P. L., Wadley, V. G., . . . Riley, W. T. (2016). Blood Pressure, Sexual Activity, and Dysfunction in Women With Hypertension: Baseline Find- ings From the Systolic Blood Pressure Intervention Trial (SPRINT). The Journal of Sexual Medicine, 13(9), 1333-1346. doi:10.1016/j. jsxm.2016.06.014
• Hanon, O., Mounier-Vehier, C., Fauvel, J. P., Marquand, A., Jabou- reck, O., Justin, E. P., . . . Girerd, X. (2002). [Sexual dysfunction in treated hypertensive patients. Results of a national survey] . Ar- chives des Maladies du Coeur et des Vaisseaux, 95(7-8), 673-677
• Healy, D., Le Noury, J., &Mangin, D. (2018). Enduring sexual dys- function after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. The International Journal of Risk & Safety in Medicine, 29(3-4), 125-134. doi:10.3233/JRS- 180744
• Imprialos, K. P., Stavropoulos, K., Doumas, M., Tziomalos, K., Kara- giannis, A., &Athyros, V. G. (2018). Sexual Dysfunction, Cardiovas- cular Risk and Effects of Pharmacotherapy. Current Vascular Phar- macology, 16(2), 130-142. Doi:10.2174/1570161115666170609101502
• Ismail, S. B., Noor, N. M., Hussain, N. H. N., Sulaiman, Z., Shamsudin, M. A., & Irfan, M. (2019). Angiotensin Receptor Blockers for Erectile Dysfunction in Hypertensive Men: A Brief Meta-Analysis of Ran- domized Control Trials. American Journal of Men’s Health, 13(6), 1557988319892735. Doi:10.1177/1557988319892735
• Kessler, A., Sollie, S., Challacombe, B., Briggs, K., & Van Hemelrijck, M. (2019). The global prevalence of erectile dysfunction: a review. British Journal of Urology, doi:10.1111/bju.14813
• Kretchy, I. A., Boima, V., Agyabeng, K., Koduah, A., & Appiah, B. (2020). Psycho-behavioural factors associated with medication adherence among male out-patients with hypertension in a Gha- naian hospital. PLoS One, 15(1), e0227874-e0227874. doi:10.1371/ journal.pone.0227874
• Krüger, T. H., Haake, P., Chereath, D., Knapp, W., Janssen, O. E., Ex- ton, M. S., . . . Hartmann, U. (2003). Specificity of the neuroendo- crine response to orgasm during sexual arousal in men. Journal of Endocrinology, 177(1), 57-64. doi:10.1677/joe.0.1770057
• Motofei, I. G., & Rowland, D. L. (2005). The physiological basis of human sexual arousal: neuroendocrine sexual asymmetry. Inter- national Journal of Andrology, 28(2), 78-87. doi:10.1111/j.1365- 2605.2004.00514.x
• Lewis, R. W., Fugl-Meyer, K. S., Corona, G., Hayes, R. D., Laumann, E. O., Moreira, E. D., Jr., . . . Segraves, T. (2010). Definitions/epidemiol- ogy/risk factors for sexual dysfunction. The Journal of Sexual Medi- cine, 7(4 Pt 2), 1598-1607. doi:10.1111/j.1743-6109.2010.01778.x
• Nicolai, M. P., Liem, S. S., Both, S., Pelger, R. C., Putter, H., Schalij, M. J., &Elzevier, H. W. (2014). A review of the positive and negative ef- fects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. Netherlands Heart Journal, 22(1), 11-19. doi:10.1007/s12471-013-0482-z
• Nilsson, P. M., Viigimaa, M., Giwercman, A., &Cifkova, R. (2020). Hy- pertension and Reproduction. Current Hypertension Reports, 22(4), 29. doi:10.1007/s11906-020-01036-2
• Oshodi, O. Y., Adeyemi, J. D., Oke, D. A., & Seedat, S. (2010). Sexual dysfunction among subjects with hypertension in a Nigerian teaching hospital. Nigerian Quarterly Journal of Hospital Medicine, 20(4), 197-204
• Oyelade, B. O., Jemilohun, A. C., &Aderibigbe, S. A. (2016). Preva- lence of erectile dysfunction and possible risk factors among men of South-Western Nigeria: a population based study. The Pan Afri- can Medical Journal, 24, 124. doi:10.11604/pamj.2016.24.124.8660
• Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997). The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology, 49(6), 822-830. doi:10.1016/s0090-4295(97)00238-0
• Santi, D., Granata, A. R., Guidi, A., Pignatti, E., Trenti, T., Roli, L., . .. Simoni, M. (2016). Six months of daily treatment with varde- nafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erec- tile dysfunction: a randomized, double-blind, prospective trial. European Journal of Endocrinology, 174(4), 513-522. doi:10.1530/ eje-15-1100
• Spatz, E. S., Canavan, M. E., Desai, M. M., Krumholz, H. M., & Lindau, S. T. (2013). Sexual activity and function among middle-aged and older men and women with hypertension. Journal of Hyperten- sion, 31(6), 1096-1105. doi:10.1097/HJH.0b013e32835fdefa
• Viigimaa, M., Vlachopoulos, C., Doumas, M., Wolf, J., Imprialos, K., Terentes-Printzios, D., . . . Mancia, G. (2020). Update of the position paper on arterial hypertension and erectile dysfunc- tion. Journal of Hypertension, 38(7), 1220-1234. doi:10.1097/ hjh.0000000000002382